Assessment of biological variation and analytical imprecision of CA 125, CEA, and TPA in relation to monitoring of ovarian cancer

Gynecologic Oncology

Volumn 74, Issue 1, 1999, Pages 12-22

  Tuxen, Malgorzata K ^a   Sölétormos, György ^a,b   Petersen, Per Hyltoft ^c   Schiøler, Vibeke ^a   Dombernowsky, Per ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Analytical variation; Biological variation; CA 125; CEA; Critical difference; Index of individuality; Ovarian cancer; TPA

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; DATA ANALYSIS; DIAGNOSTIC VALUE; FEMALE; HUMAN; NORMAL HUMAN; OVARY CANCER; PATIENT MONITORING; PRIORITY JOURNAL;

EID: 0345593761     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5414     Document Type: Article

References (42)

1. Bast R C, Feeney M, Lazarus H, Nadler L M, Colvin R B, Knapp R C. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 68:1981;1331-1337.
2. Tuxen M K, Sölétormos G, Dombernowsky G. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 21:1995;215-245.
3. Buamah P K, Skillen A W. Serum CA 125 concentrations in patients with benign ovarian tumours. J Surg Oncol. 56:1994;71-74.
4. Mozas J, Castilla J A, Jimena P, Gil T, Acebal M, Herruzo A J. Serum CA 125 in the diagnosis of acute pelvic inflammatory disease. Int J Gynecol Obstet. 44:1994;53-57.
5. Patton P E, Field C S, Harms R W, Coulam C B. CA 125 levels and endometriosis. Fertil Steril. 45:1986;770-773.
6. Molina R, Ballesta A M, Casals E, Borras G, Elena M, Balaue A. Value of CA 125 antigen as tumour marker: Preliminary results. Protides Biol Fluids. 32:1984;613-616.
7. Duk J M, Aalders J G, Fleuren G J, De Bruijn H WA. CA 125: A useful marker in endometrial carcinoma. Am J Obstet Gynecol. 155:1986;1097-1102.
8. Gold P, Freedman S O. Specific carcinoembryonic antigen of the human digestive system. J Exp Med. 122:1965;467-481.
9. Tsavaris N, Vonorta K, Tsoutsos H, Kozatsani-Halividi D, Mylonakis N, Papagrigorion D, Koutsiouba-Kazakon P, Kosmidis P. Carcinoembryonic antigen (CEA), a-fetoprotein, CA 19.9 and CA 125 in advanced colorectal cancer (ACC). Int J Biol Markers. 8:1993;88-93.
10. Chevinsky A H. CEA in tumors of other than colorectal origin. Semin Surg Oncol. 7:1991;162-166.
11. Luning B, Redelius P, Wiklund B, Bjorklund B. Chemical studies of TPA. Prot Biol Fluids Proc Colloq. 24:1976;513-520.
12. Sundstöm B E, Stigbrand I T. Cytokeratins and tissue polypeptide antigen. Int J Biol Markers. 9:1994;102-108.
13. Inoue M, Inoue Y, Hiramatsu K, Ueda G. The clinical value of tissue polypeptide antigen in patients with gynecologic tumors. Cancer. 55:1985;2618-2623.
14. Menendez-Botet C J, Oettgen H F, Pinsky C M, Schwartz M K. A preliminary evaluation of tissue polypeptide antigen in serum or urine (or both) in patients with cancer or benign neoplasms. Clin Chem. 6:1978;868.
15. Fraser C G, Hyltoft Petersen P, Larsen M L. Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem. 36:1990;1625-1628.
16. Kenemans P, van Kamp G J, Oehr P, Verstraeten R A. Heterologous double-determinant immunoradiometric assay CA 125 II: Reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem. 39:1993;2509-2513.
17. Pharmacia CEA RIA, Radioimmunoassay, Kabi Pharmacia Diagnostics, Uppsala, Sweden, [package insert, March 1993].
18. Prolifigen TPA IRMA, Immunoradiometric assay for the quantification of tissue polypeptide antigen (TPA), Sangtec Medical, Bromma, Sweden, [package insert, 1994].
19. Westgard J O, Groth T. Design and evaluation of statistical control procedures: Applications of a computer "quality control simulator" program. Clin Chem. 27:1981;1536-1545.
20. Kan Y Y, Yeh S H, Ng H T, Lou C M. Effect of menstruation on serum CA 125 levels. Asia-Oceania J Obstet Gynaecol. 18:1992;339-343.
21. Fraser C G, Harris E K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci. 27:1989;409-437.
22. Bliss, C, I, Statistics in Biology, New York, McGraw-Hill, 1967, Vol, 1.
23. Fraser C G, Hyltoft Petersen P. The importance of imprecision. Ann Clin Biochem. 28:1991;207-211.
24. Plebani M, Giacomini A, Beghi L, De Paoli M, Roveroni G, Galeotti F, Corsini A, Fraser C G. Serum tumor markers in monitoring patients: Interpretation of results using analytical and biological variation. Anticancer Res. 16:1996;2249-2252.
25. Browning M CK, McFarlane N P. Objective interpretation of results for tumor markers. J Nucl Med Allied Sci. 34:1990;89-91.
26. Sölétormos G, Schiøler V, Nielsen D, Skovsgaard T, Dombernowsky P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem. 39:1993;2077-2083.
27. Fraser C G. Data on biological variation: essential prerequisites for introducing new procedures. Clin Chem. 40:1994;1671-1673.
28. Harris E K. Distinguishing physiologic variation from analytic variation. J Chron Dis. 23:1970;469-480.
29. Fraser C G, Fogarty Y. Interpreting laboratory results. Analytical and biological variation must be taken into account. Br Med. 298:1989;1659-1660.
30. Gion M, Barioli P, Mione R, Cappelli G, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M. Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessment. Ann Oncol. 6:1995;31-35.
31. Sölétormos G, Nielsen D, Schiøler V, Skovsgaard T, Dombernowsky P. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem. 42:1996;564-575.
32. Sölétormos G, Nielsen D, Schiøler V, Skovsgaard T, Winkel P, Mouridsen H T, Dombernowsky P. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol. 4:1993;861-869.
33. Hölzel W GE, Beer R, Deschner W, Griesmacher A, Müller M M. Individual reference ranges of CA 15-3, MCA and CEA in recurrence of breast cancer. Scand J Clin Lab Invest. 55:1995;93-101.
34. Mora J, Queralto J M. Within-subject variation of carcinoembryonic antigen in colorectal cancer - Application of reference change values and individual reference ranges to patient follow-up. Eur J Clin Chem Clin Biochem. 35:1997;453-457.
35. Bon G G, Kenemans P, Verstraeten R, van Kamp G J, Hilgers J. Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values. Am J Obstet Gynecol. 174:1996;107-114.
36. Grover S, Quinn M A, Weideman P, Koh H. Factors influencing serum CA 125 levels in normal women. Obstet Gynecol. 79:1992;511-514.
37. Haga Y, Sakamoto K, Egami H, Yoshimura R, Akagi M. Evaluation of serum CA 125 values in healthy individuals and pregnant women. Am J Med Sci. 292:1986;25-29.
38. Zurawski V R, Broderick S F, Pickens P, Knapp R C, Bast R C. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol. 69:1987;606-611.
39. Westhoff C, Gollub E, Patel J, Rivera H, Bast R Jr. CA 125 levels in menopausal women. Obstet Gynecol. 76:1990;428-431.
40. Green P J, Ballas S K, Westkaemper P, Schwartz H G, Klug T L, Zurawski V R Jr. CA 19-9 and CA 125 levels in the sera of normal blood donors in relation to smoking history. J Natl Cancer Inst. 77:1986;337-341.
41. Hansen H J, Snyder J J, Miller E, Vandevoorde J P, Milelr O N, Hines L R, Burns J J. Carcinoembryonic antigen (CEA) assay. A laboratory adjunct in the diagnosis and management of cancer. J Hum Pathol. 5:1974;139-147.
42. Stevens D P, Mackay I R. Increased carcinoembryonic antigen in heavy cigarette smokers. Lancet. 2:1973;1238-1239.